Welcome to our dedicated page for Columbus Circle Cap Ii SEC filings (Ticker: CMII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Columbus Circle Cap Ii's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Columbus Circle Cap Ii's regulatory disclosures and financial reporting.
Columbus Circle Capital Corp filed its annual report outlining its status as a newly formed SPAC with no operating revenues and no Business Combination target yet selected. The company completed an IPO of 23,000,000 units at $10.00 each, raising gross proceeds of $230,000,000, and a concurrent private placement of 665,000 units for $6,650,000.
A total of $230,000,000 from the IPO and private placement was placed in a trust account to fund a future Business Combination, with public shareholders entitled to redeem at about $10.00 per share. The SPAC must complete a Business Combination by February 12, 2028 or liquidate and return trust funds to public shareholders.
As of March 30, 2026 there were 23,665,000 Class A ordinary shares and 7,666,667 Class B ordinary shares outstanding. The filing highlights substantial potential dilution from founder shares, private placement units, working capital loans convertible into up to 150,000 additional private Class A shares, and associated warrants exercisable at $11.50 per share.